Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYN-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Funding
Synergys Receives Third NIH SBIR Grant from National Cancer Institute
Details : The grant will support ongoing preclinical development of the Company’s lead biological drug candidate, SYN-001, as a treatment for Triple Negative Breast Cancer (TNBC).
Product Name : SYN-001
Product Type : Peptide
Upfront Cash : Undisclosed
October 10, 2022
Lead Product(s) : SYN-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Undisclosed
Deal Type : Funding